CAROLINA PHARMACY NETWORK JOINS PPSC BUYING GROUPS, bringing the purchasing power of Pharmacy Provider Services Corporation Group (PPSC) to more than 3,000 pharmacies nationwide. In an Aug. 22 release, PPSC announced that "Carolina Pharmacy Network (CPN) has contracted with PPSC for group purchasing program implementation and operational assistance." The Carolina network provides services to pharmacy owners throughout South Carolina. PPSC, first coordinated by the Florida Pharmacy Association in 1984, now has pharmacy members in 21 states, including Texas, Illinois, Wisconsin, Maine, Vermont, Massachusetts, Florida, Louisiana, and a large representation from the southeast U.S. The corporation has contracts with roughly 40 vendors/manufacturers for over 2,000 products. According to PPSC, the Carolina Pharmacy Network is now in the process of selecting participating wholesalers in South Carolina. The group anticipates that the type of products and implementation will be similar to that of the overall PPSC operation. Pharmacies in the buying group receive products at wholesaler's cost. The wholesaler then receives a "chargeback" from the vendor for the difference between the buying group's contracted price and the regular wholesale price. The "chargeback" is a way "to keep control on who is getting the pricing," added PPSC. "This way there's a track record being kept on where those products are going." PPSC said that each month the corporation gives the vendors a list of all the participating pharmacies. Addressing the buying groups' panel session at the National Association of Retail Druggists' first annual PSAO (pharmacy services administrative organization) conference last May, PPSC Senior VP William Mincy said that PPSC also uses generic price ceilings -- a kind of MAC. If the pharmacist can buy below the set price, he can keep the difference. Currently, PPSC is in the process of sending out new pharmaceutical comparative proposals to vendors. The corporation reviews the competitive proposals once a year for Rx and OTC drugs. In addition, new products are addressed by the group "on a case-by-case basis," as they are introduced.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”
